United Therapeutics Corp. (NASDAQ:UTHR) experienced notable activity in its executive stock holdings recently, particularly involving Chairperson and CEO Martine A. Rothblatt. On May 13, 2026, Ms. Rothblatt executed a transaction resulting in the sale of 9,500 shares of the company's common stock. The total value generated from this disposition was approximately $5.5 million. It is important to note that these sales followed the prior exercise of stock options for an equal number of shares.
The timing of this insider activity comes as United Therapeutics shares are trading close to their 52-week peak, with the stock having risen by 92% over the past year. An analysis from InvestingPro suggests that, relative to its Fair Value, the stock currently appears overvalued among other key insights provided in the comprehensive Pro Research Report covering UTHR and more than 1,400 other US equities.
Details of the Transaction
The specific sales executed on May 13, 2026, involved a total of 9,500 shares of common stock. These shares were sold at prices that ranged between $575.402 and $583.81 per share, culminating in a collective value of $5,497,166.
Earlier in the process, prior to the sale, Ms. Rothblatt had acquired 9,500 shares of common stock by exercising options. This option exercise occurred at a lower price point of $146.03 per share, amounting to an initial cost base of $1,387,285.
Both the option exercise and the subsequent sale were managed under the framework of a pre-arranged 10b5-1 trading plan. This structured plan was initially adopted by Ms. Rothblatt on November 7, 2025. The terms of this plan dictate that it will remain active until one of two conditions is met: either all 1,734,410 stock options expire on March 17, 2027, or the date reaches December 31, 2026, whichever occurs first.
Broader Corporate Context and Holdings
While the CEO has been actively selling shares, available InvestingPro data indicates that management has simultaneously engaged in aggressive share buybacks. This pattern of activity suggests a level of internal confidence concerning the company's $24.4 billion market capitalization business.
Following these recent transactions, Ms. Rothblatt’s direct ownership stake in United Therapeutics common stock totals 40,513 shares. Her indirect holdings are also significant and include:
- 166 shares held indirectly through her spouse.
- 324,443 shares within family trusts where she shares investment power and is a beneficiary.
- 258,117 shares where her spouse serves as the sole or co-trustee.
- 45,596 shares where her spouse shares investment power.
- 10,962 shares where she is the sole or co-trustee.
Furthermore, Ms. Rothblatt maintains a direct holding of 240,410 stock options.
Recent Operational and Strategic Developments
In separate company updates, United Therapeutics disclosed its first-quarter earnings results for the year 2026. These financials fell short of what analysts had projected. The company reported earnings per share (EPS) of $5.82, missing the forecasted figure of $6.99. Revenue was also reported at $782 million, falling slightly below the anticipated $798.85 million.
Specific to its Tyvaso division, revenues amounted to $457.5 million, failing to meet the consensus estimate of $478.6 million. In response to these figures, BTIG maintained a Neutral rating on United Therapeutics’ stock.
On a positive strategic note, United Therapeutics announced a partnership with Varda Space Industries. This collaboration is focused on exploring pharmaceutical processing techniques that utilize microgravity conditions for the treatment of rare pulmonary diseases. The initiative plans to leverage Varda's orbital manufacturing and reentry platform to conduct necessary pharmaceutical processing during missions traveling to low Earth orbit. The goal of this alliance is to capitalize on microgravity’s potential effects on therapeutic compounds, thereby enhancing their stability, bioavailability, and overall delivery characteristics.
Key Takeaways for Analysis
The current data presents a mix of signals. On one hand, the CEO's sale of shares following option exercise is noted alongside an overvaluation warning from ProResearch analysis. On the other hand, management's reported aggressive buying activity suggests internal belief in the company's long-term value. Furthermore, while Q1 2026 earnings and Tyvaso revenues missed expectations, the partnership with Varda Space Industries introduces a high-technology, potentially transformative element into the corporate strategy, focusing on novel drug delivery via space.